Antibodies have been powerful tools for inhibiting a targeted protein. Abalone Bio is pursuing a new class of antibody therapies called activating antibodies that can regulate cellular processes and restore their balance. One aspect that makes these rare antibodies attractive is that they can target previously undruggable G protein-coupled receptors, allowing them to treat diseases that have been hard to address. We spoke to Richard Yu, co-founder and CEO of Abalone Bio, about activating antibodies, how the company generates massive data sets for its AI-driven platform technology, and how it looks beyond binding to explore the function of these antibodies.
